Literature DB >> 29157037

Fetal nuchal translucency in severe congenital heart defects: experiences in Northern Finland.

Julia Alanen1, Markku Leskinen2, Mikko Sairanen3, Teemu Korpimaki3, Heikki Kouru3, Mika Gissler4, Markku Ryynanen1, Jaana Nevalainen1.   

Abstract

OBJECTIVE: To evaluate the performance of first-trimester measurement of fetal nuchal translucency (NT) in the detection of severe congenital heart defects (CHDs).
METHODS: During the study period of 1 January 2008 - 31 December 2011, NT was measured in 31,144 women as a part of voluntary first-trimester screening program for Down's syndrome in Northern Finland. NT was measured by personnel trained on the job by the experienced staff. No certification or annual audits are required in Finland. However, the recommendation is that the examiner should perform 200 scans on average per year. Severe CHD was classified as a defect requiring surgery in the first year of life or a defect that led to the termination of the pregnancy. All severe CHDs diagnosed during the study period in Northern Finland could not be included in this study since all women did not participate in the first-trimester screening and some cases were missing important data.
RESULTS: Fourteen (17.7%) out of 79 severe CHDs were found with NT cutoff of 3.5 mm. Amongst the 79 severe CHD cases, there were 17 chromosomal abnormalities. With NT cutoffs of 2.0 and 1.5 mm the detection rates would have increased to 25.3% (n = 20) and 46.8% (n = 37). Using a randomly selected control group of 762 women with normal pregnancy outcomes, false positive rates (FPRs) were calculated. For NT cutoffs of 1.5, 2.0 and 3.5 mm, the FPRs were, 18.5, 3.3 and 0.4%, respectively.
CONCLUSIONS: A greater than 3.5 mm NT measurement in the first-trimester ultrasound is an indication to suspect a fetal heart defect but its sensitivity to detect severe CHD is poor. In our study, only 17.7% of severe CHDs would have been detected with an NT cutoff of 3.5 mm.

Entities:  

Keywords:  Birth defect; Down’s syndrome; congenital heart defect; fetal screening; first-trimester screening; nuchal translucency

Mesh:

Year:  2017        PMID: 29157037     DOI: 10.1080/14767058.2017.1408067

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  4 in total

Review 1.  [Relevant aspects of the ESC guidelines for the management of cardiovascular diseases during pregnancy for obstetric anaesthesia (update 2018)].

Authors:  S Brück; U Seeland; E Kranke; P Kranke
Journal:  Anaesthesist       Date:  2019-07       Impact factor: 1.041

2.  Levels of Circulating mRNA for the Tenascin-X (TNXB) Gene in Maternal Plasma at the Second Trimester in Pregnancies with Isolated Congenital Ventricular Septal Defects.

Authors:  Danila Morano; Silvia Berto; Cristina Lapucci; Lara Walczer Baldinazzo; Daniela Prandstraller; Antonio Farina
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

3.  Risk Assessment of the Increased Occurrence of Congenital Cardiac and Non-Cardiac Defects in Fetuses with a Normal Karyotype after Assisted Fertilization in Comparison to Natural Fertilization Based on Ultrasound Diagnostics.

Authors:  Dawid Serafin; Beniamin Oskar Grabarek; Dariusz Boroń; Andrzej Madej; Bartosz Czuba
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

4.  Chromosomal microarray analysis versus noninvasive prenatal testing in fetuses with increased nuchal translucency.

Authors:  Chaohong Wang; Junxiang Tang; Keting Tong; Daoqi Huang; Huayu Tu; Jiansheng Zhu
Journal:  J Hum Genet       Date:  2022-05-17       Impact factor: 3.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.